Compare WLY & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLY | ZLAB |
|---|---|---|
| Founded | 1807 | 2013 |
| Country | United States | China |
| Employees | 5200 | N/A |
| Industry | Books | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | N/A | 2017 |
| Metric | WLY | ZLAB |
|---|---|---|
| Price | $51.11 | $20.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.60 |
| AVG Volume (30 Days) | 690.4K | ★ 851.8K |
| Earning Date | 06-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | $1.04 | $9.75 |
| Revenue Next Year | $2.36 | $26.03 |
| P/E Ratio | $15.84 | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $28.38 | $15.96 |
| 52 Week High | $53.24 | $41.20 |
| Indicator | WLY | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 63.50 |
| Support Level | $37.01 | $16.84 |
| Resistance Level | $53.24 | $21.33 |
| Average True Range (ATR) | 2.20 | 0.84 |
| MACD | -0.16 | 0.19 |
| Stochastic Oscillator | 71.60 | 93.46 |
John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.